MiniMed Group (MMED) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

—

Estimate

$0.10

Surprise

-100.0%

Score today

5.6/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

• Morgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21 — benzinga, 2026-09-03
• Citigroup Maintains Buy on Minimed Group, Raises Price Target to $26 — benzinga, 2026-09-02
• Evercore ISI Group Maintains Outperform on Minimed Group, Raises Price Target to $27 — benzinga, 2026-09-02

TrendMatrix currently rates MMED Sell at 5.6/10; no pre/post engine snapshot brackets this report.

1 of the last 3 quarters beat the estimate; this quarter's -100.0% surprise compares with a -65.9% four-quarter average. Next scheduled report: 2026-11-16.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$20.54

Price target

$21.35

Stop

$19.10

Upside to target

+3.9%

Reward-to-risk

0.4:1

Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Instruments & Supplies

Market cap

$5.78B

P/E (fwd)

32.2

52-week range

$10.65–$24.43

Off 52-week high

15.9%

RSI (14)

15

Volume vs avg

1.08×

Score today

5.6/10